Compare Mongodb Inc (MDB) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mongodb Inc vs TransMedics Group Inc — how do they compare? Mongodb Inc trades at $438.95 (market cap $35.32B), while TransMedics Group Inc trades at $87.58 (market cap $3.10B). The key difference: Mongodb Inc is far larger — about 11.4× TransMedics Group Inc's market cap, and Mongodb Inc is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| MDB | TMDX | |
|---|---|---|
Market Cap | $35.32B | $3.10B |
Sector | Technology | Technology |
52-Week High | $440.25 | $150.42 |
52-Week Low | $204.37 | $61.99 |
Enterprise Value | $32.93B | $3.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MDB trades at $436.91, up 4.86% over the past day, with a bullish technical signal from moving averages and strong analyst sentiment. Revenue growth is robust, reaching $2.01B in 2025, though the company remains unprofitable with a net income margin of -1.12%. Recent earnings beats and an upcoming Q2 2026 report on September 1, 2026, highlight operational momentum amid high institutional interest.
The outlook is positive given consistent earnings outperformance and projected revenue growth to $2.6B in 2026. Risks include persistent losses, competitive pressures, and high valuation multiples. With 82% of analysts rating it a buy and a consensus price target of $404.30, the stock offers growth potential but requires monitoring of profitability trends.
TransMedics Group (TMDX) trades at $87.42, down 1.12% on the day, with a bullish technical outlook from moving averages but bearish oscillators signaling potential overbought conditions. The company reported mixed Q2 2026 results, missing earnings estimates with EPS of $0.44 versus $0.50 expected, while revenue growth remains robust. Recent news highlights an ongoing investigation into fiduciary duties by directors, adding uncertainty.
The stock presents a cautious opportunity with strong analyst support (69% buy ratings) and a consensus price target of $99.57, implying upside, but risks include earnings volatility, margin pressures, and legal scrutiny. Fundamentals show solid profitability with a 22.69% net margin, though valuation multiples like P/E of 23.15 suggest premium pricing relative to historical norms.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mongodb Inc
Founded in 2007, MongoDB is a document-oriented database with nearly 33,000 paying customers and well past 1.5 million free users. MongoDB provides both licenses as well as subscriptions as a service for its NoSQL database. MongoDB's database is compatible with all major programming languages and is capable of being deployed for a variety of use cases.
Read more on MDB →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
